Symptomatic (postencephalitic, toxic or arterio-sclerotic) parkinsonism, except drug-induced parkinsonism, parkinson's disease.

Levodopa is the metabolic precursor of dopamine. Benserazide is a peripheral decarboxylase inhibitor, which blocks the extracerebral decarboxylation of levodopa.

The bioavailablilty of Madopar HBS is 60%. After ingestion of HBS form need 3 hours to achieve serum peak concentration.

Severely de-compensated endocrine, renal, hepatic, cardiac disorders; psychosis and severe psychoneurosis; patient under 25 years old (due to possibility of skeletal abnormalities from benserazide); pregnant women; use of MAO inhibitors within prior 14 days; narrow-angle glaucoma or closed-angle glaucoma.

Avoided.

Anorexia, nausea, and vomiting, psychic disturbance. The effects of levodopa are reduced or abolished by the concurrent use of vitamin B6 but no interaction occurred with levodopa-carbidopa or levodopa-benserazide preperations.

Initial dose: 125mg TID then increased by 125mg weekly until the individual therapeutic dosage is reached up to 1000 mg/day QID.Capsules should be swallowed whole; Do Not crush, chew, open, or dissolve in liquid.